Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rituximab-induced interstitial lung disease.

Stephanie A Wagner1, Apurva C Mehta, Damian A Laber

  • 1Division of Hematology and Medical Oncology, University of Louisville, J.G. Brown Cancer Center, Louisville, Kentucky, USA. stephanie.wagner@insightbb.com

American Journal of Hematology
|June 29, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of Recurrent Venous Thromboembolism on Anticoagulation.

Journal of clinical medicine·2026
Same author

Direct Oral Anticoagulants in Budd-Chiari Syndrome.

European journal of haematology·2024
Same author

Impact of Phlebotomy on Quality of Life in Low-Risk Polycythemia Vera.

Journal of clinical medicine·2024
Same author

Support Through Remote Observation and Nutrition Guidance (STRONG), a digital health intervention to reduce malnutrition among pancreatic cancer patients: A study protocol for a pilot randomized controlled trial.

Contemporary clinical trials communications·2024
Same author

Complement-mediated thrombotic microangiopathy treated with anticomplement protein 5 therapy, a retrospective study.

European journal of haematology·2023
Same author

Enhanced Efficacy of Chemotherapy by Addition of Immune Checkpoint Inhibitors in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung: A Real-World Analysis.

Journal of Cancer·2023
Same journal

High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1.

American journal of hematology·2026
Same journal

Peripheral Blood Lymphocytosis Reflecting an Underlying Thymoma.

American journal of hematology·2026
Same journal

Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children.

American journal of hematology·2026
Same journal

Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management.

American journal of hematology·2026
Same journal

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

American journal of hematology·2026
Same journal

Comparative Efficacy of Intranasal, Intramuscular, and Intravenous Vitamin B12 Therapy for Hematological Recovery in Vitamin B12 Deficiency Anemia: A Randomized Controlled Trial.

American journal of hematology·2026
See all related articles

Rituximab-induced interstitial lung disease (R-ILD) is a rare, potentially fatal toxicity. Early recognition of R-ILD symptoms like dyspnea and prompt corticosteroid treatment are crucial for patient outcomes.

Area of Science:

  • Pulmonology
  • Rheumatology
  • Oncology

Background:

  • Rituximab is a chimeric monoclonal antibody used in treating various autoimmune diseases and cancers.
  • Interstitial lung disease (ILD) is a known, albeit rare, adverse effect associated with rituximab therapy, termed R-ILD.
  • The precise pathogenesis and clinical spectrum of R-ILD require further elucidation.

Observation:

  • A review of 16 reported cases of R-ILD, including two new cases, identified commonalities in patient demographics, clinical presentations, and diagnostic findings.
  • Common features include older patient age, specific clinical symptoms (dyspnea, fever, cough), characteristic findings on computed tomography (CT) scans, pulmonary function tests, and lung biopsies.
  • Therapeutic interventions primarily involved corticosteroids and broad-spectrum antibiotics.

Related Experiment Videos

Findings:

  • R-ILD presents with a variable prognosis, with patients showing poor outcomes despite corticosteroid treatment.
  • The exact pathogenesis of R-ILD remains largely unknown, with theories suggesting the induction and release of cytotoxic substances.
  • Key diagnostic indicators include dyspnea, fever, and cough in patients receiving rituximab, especially when infection is not evident.

Implications:

  • R-ILD represents a significant, potentially fatal pulmonary toxicity that necessitates clinical vigilance.
  • Healthcare providers should consider R-ILD in patients presenting with relevant respiratory symptoms post-rituximab therapy.
  • Prompt diagnosis and initiation of corticosteroid treatment are critical for managing R-ILD and improving patient prognosis.